Fluticasone propionate: a large multicentre trial

Dolovich, J.; Anderson, Milton W.; Chodirker, William B.; Drouin, M.; Fe, Hargreave; Hébert, Jacques; Knight, Allan; O'Conner, M.; Small, Peter; Yang, WH

doi:10.1016/s0954-6111(08)80005-4

Cited by 14 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FPANS administered once a day appeared to be effective for a full day, confirming previous observations both in adults (5,8,19,23) and in children (9,14,21). Compared with the recommended use of BDP four times daily, the administration once a day of FPANS offers the obvious advantage that parents can supervise the correct use of the spray more easily and consistently throughout the treatment period, with an expected improvement in compliance (16).…”

Section: Discussionsupporting

confidence: 89%

“…The local side-effects, spray-induced sneezing, nose dryness, and nose bleeding, were carefully recorded in our study, and we did not find any difference between active and placebo treatment. These results confirm those of other placebo-controlled studies in which the tolerability of FP was evaluated both in adults (8,15,19,24,28,30) and children (9,14,17,21).…”

Section: Discussionsupporting

confidence: 88%

“…There were no statistically significant differences between the FPANS 100 ^tg and FPANS 200 |ig groups in improvement in nasal symptoms scores, although, in the more severe cases studied, there did appear to be a benefit in using a dose of 200 \ig od without any concomitant decrease in tolerability. This phenomenon was also observed in adults (8).…”

Section: Discussionsupporting

confidence: 72%

“…In view of this lack of systemic activity and the finding in adults and adolescents that FPANS 200 ^g given once daily is effective and well tolerated in the treatment of seasonal allergic rhinitis in a number of placebo-controlled and comparator studies (8,14,23), it was decided to examine the absolute efficacy and tolerability of FPANS 200 |j,g once daily and FPANS 100 jig once daily in children with seasonal allergic rhinitis.…”

mentioning

confidence: 99%

See 3 more Smart Citations

The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis

Boner

Sette

Martinati

et al. 1995

Allergy

View full text Add to dashboard Cite

Fluticasone propionate aqueous nasal spray (FPANS) contains fluticasone propionate, which is a new topically active glucocorticoid with approximately twice the potency of belcomethasone dipropionate. In this European multicentre study, 143 children with seasonal allergic rhinitis were recruited: 47 received FPANS 100 micrograms once a day (od), 46 received FPANS 200 micrograms od, and 50 patients received placebo od, for 4 weeks. Treatment efficacy was assessed using diary card nasal symptom scores for sneezing, rhinorrhoea, blockage and itching, and eye watering/irritation. Patients receiving FPANS 100 micrograms or FPANS 200 micrograms demonstrated statistically significant improvements in median nasal symptom scores in all the symptoms recorded, when compared with placebo. There were no statistically significant differences between the FPANS 100 micrograms and FPANS 200 micrograms groups in improvement in nasal symptom scores. There was no effect on eye watering/irritation symptoms which could be attributed to either FPANS 100 micrograms or FPANS 200 micrograms when compared with placebo. Use of rescue antihistamine medication was significantly reduced in the FPANS 100 micrograms group when compared with placebo. The adverse events profile was similar in all three treatment groups, and the events reported were generally mild and related to the patients' rhinitis.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 72%

mentioning

confidence: 99%

See 2 more Smart Citations

The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis

Boner

Sette

Martinati

et al. 1995

Allergy

View full text Add to dashboard Cite

show abstract

“…Patients were stratified for disease severity on the basis ofthe clinical history and the size of the skin-prick test response to grass pollen. Patients were then randomized to receive 6 weeks treatment with either topical fluticasone propionate [13] 200/ig twice daily (two sprays to each nostril twice daily) or matched placebo nasal spray, in a parallel group fashion. Baseline nasal biopsies were performed oul of season (March 1991).…”

Section: Methodsmentioning

confidence: 99%

Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge

Rak

Jacobson²,

Sudderick³

et al. 1994

Clin Experimental Allergy

View full text Add to dashboard Cite

We have examined the effect of prolonged treatment with topical corticosteroid on allergen-induced early and late nasal responses and the associated inflammatory cell infiltrate in grass pollen sensitive allergic rhinitics. Following a randomized double-blind 6 week treatment period with fluticasone propionate 200 micrograms aqueous nasal spray twice daily or matched placebo spray, nasal provocation was performed using Timothy grass pollen extract. Nasal symptoms were recorded at intervals from 0 to 24 h. Nasal biopsies were performed before treatment and at 24 h after allergen and processed for immunohistology. When corticosteroid-treated patients were compared with the placebo group there was an approximately 50% decrease in the size of the early (0-60 min) response and almost complete inhibition of late (1-24 h) nasal symptoms after allergen challenge. After allergen challenge markedly fewer T lymphocytes and CD25+ (interleukin-2 receptor bearing) cells were observed in both the epithelium and submucosa in fluticasone treated patients compared with the placebo group. Significantly less total and activated eosinophils were observed, particularly within the nasal epithelium. Submucosal mast cell counts were decreased, whereas increased numbers of submucosal neutrophils were observed. These results confirm that topical corticosteroid treatment inhibits allergen-induced early and late nasal responses. This may possibly occur following a decrease in T lymphocytes and/or mast cells and their products and a consequent reduction in tissue eosinophilia.

show abstract

Topical nasal steroids for intermittent and persistent allergic rhinitis in children

Sayyad

Fedorowicz

Alhashimi

et al. 2007

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Allergic rhinitis is a very common chronic illness a ecting 10% to 40% of children worldwide. There has been a significant increase in prevalence among children over the last two decades and this increase has been accompanied by a parallel increase in comorbid illnesses such as asthma. Objectives To evaluate the therapeutic e ectiveness and adverse event profiles of topical nasal steroids for intermittent and persistent allergic rhinitis in children.

show abstract

Fluticasone propionate: a large multicentre trial

Cited by 14 publications

References 0 publications

The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis

The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis

Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge

Topical nasal steroids for intermittent and persistent allergic rhinitis in children

Contact Info

Product

Resources

About